Noxopharm Ltd has released a press release.
Veyonda Achieves Important U.S. Patent Claims
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
- Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
- Pre-clinical Data Supports a Role for Veyonda in COVID-19
- NOXCOVID Program to Expand After Positive Phase 1 Results
- Noxopharm: Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
Later from Noxopharm
- September 2021 Quarterly Activities Report and Appendix 4C
- Patent Granted for Veyonda and Low Dose Chemotherapy
- Veyonda and Opdivo IONIC Study First Patient Dosed
- Noxopharm Announces DARRT-2 Clinical Trial in U.S.
- Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm